Founded in 2014, OSSIO aims to transform orthopedic surgery by replacing traditional metal implants with its proprietary OSSIOfiber Intelligent Bone Regeneration Technology. The company’s bio-integrative implants are designed to provide strong fixation while naturally integrating with bone, eliminating the need for hardware removal and improving patient outcomes. Product development and manufacturing are conducted in Caesarea, Israel, while commercial operations are headquartered in Palmetto, Florida. Management plans to use additional growth capital to accelerate global expansion of the technology across the multibillion-dollar orthopedic fixation market. OSSIO positions itself as a disruptive alternative for patients, physicians, providers and payors seeking better clinical and economic value. Although no revenue or user metrics were disclosed, the firm emphasizes rapid commercialization and international scaling. The recent financing partnership underscores OSSIO’s focus on maintaining its mission while gaining the resources required for broader market penetration.

Total raised

$158M

Funding rounds

5

Latest round

Debt Financing

Latest activity

Feb 2026